Prof. Roberto Gambari and the ThalLab have been involved in the
development of novel approaches for molecular diagnosis of thalassaemia biosensors
and surface plasmon resonance technology. Prof. Gambari's group is involved in innovative
projects in the field of nanotechnology, focusing on the development of novel lab-on-a-chip
platforms for diagnostic and therapeutic applications. Moreover, Prof. Gambari has
produced several research papers and patents on induction of fetal haemoglobin as
a possible tool for the therapy of thalassaemia. The main target of this work has
been the development of innovative therapeutic strategies based on novel drugs for
treatment of thalassaemia and sickle-cell anaemia.
The major aims of
Dr Gambari's group are
- identification and characterisation of inducers of fetal haemoglobin (HbF)
- development of animal model systems to test HbF inducers
- development of suitable delivery systems for in-vivo treatment.